New data from three clinical trials show Zometa® (zoledronic acid) reduced the risk of local and distant recurrence in pre- and post-menopausal women with early-stage breast cancer. Investigators reported on the studies this week in Stockholm at the 33rd Annual Congress of the European Society for Medical Oncology (ESMO), the primary European professional organization representing medical oncologists.
More...